HES-1 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: HES-1 Antibody [NBP1-30912] -

HES-1 antibody [N1], N-term detects HES-1 protein at nucleus by immunofluorescent analysis.
Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.
Green: HES-1 protein stained by HES-1 antibody [N1], N-term (NBP1-30912) diluted at 1:2000.
Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin antibody [GT114] diluted at 1:1000.
Blue: Hoechst 33342 staining.

Western Blot: HES-1 Antibody [NBP1-30912] -

MCF-7 whole cell and nuclear extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with HES-1 antibody [N1], N-term (NBP1-30912) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Western Blot: HES-1 Antibody - BSA Free [NBP1-30912] -

Interleukin-33 (IL-33) decreases bone marrow-derived monocytes (BMMs) osteoclastogenesis by inhibiting Notch1 activity. (A) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (B–D) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (E) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors induced by IL-33 in the presence of miR-34a-5p antagomir. (F–H) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors treated with IL-33 in the presence of miR-34a-5p antagomir. (I–K) BMMs osteoclastic formation and tartrate-resistant acid phosphatase (TRAP) activity assay after treatment with 20 ng/ml IL-33 in the presence of Jag-1. Red arrows indicated multinucleated osteoclasts. Scale bars represent 100 um. (L–O) Quantification of Trap, Cathepsin K, Nfatc1, and C-fos expression in osteoclast progenitors treated with 20 ng/ml IL-33 in the presence of Jag-1. *P < 0.05, **P < 0.01, ***P < 0.001. P values were analyzed by one-way ANOVA. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29085370), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: HES-1 Antibody - BSA Free [NBP1-30912] -

Interleukin-33 (IL-33) decreases bone marrow-derived monocytes (BMMs) osteoclastogenesis by inhibiting Notch1 activity. (A) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (B–D) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (E) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors induced by IL-33 in the presence of miR-34a-5p antagomir. (F–H) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors treated with IL-33 in the presence of miR-34a-5p antagomir. (I–K) BMMs osteoclastic formation and tartrate-resistant acid phosphatase (TRAP) activity assay after treatment with 20 ng/ml IL-33 in the presence of Jag-1. Red arrows indicated multinucleated osteoclasts. Scale bars represent 100 um. (L–O) Quantification of Trap, Cathepsin K, Nfatc1, and C-fos expression in osteoclast progenitors treated with 20 ng/ml IL-33 in the presence of Jag-1. *P < 0.05, **P < 0.01, ***P < 0.001. P values were analyzed by one-way ANOVA. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29085370), licensed under a CC-BY license. Not internally tested by Novus Biologicals.